Spots Global Cancer Trial Database for plexiform neurofibromas
Every month we try and update this database with for plexiform neurofibromas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas | NCT02177825 | Plexiform Neuro... | Imatinib Mesyla... | 2 Years - 21 Years | St. Justine's Hospital | |
| Individual Patient Compassionate Use of Mirdametinib | NCT05028166 | Neurofibromatos... Histiocytic Neo... Other MAP-K Pat... | Mirdametinib (M... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | NCT05331105 | Neurofibromatos... Plexiform Neuro... | HL-085 | 18 Years - 80 Years | Shanghai Kechow Pharma, Inc. | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development | NCT00340522 | Cancer | - 25 Years | National Institutes of Health Clinical Center (CC) | ||
| Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 | NCT05238909 | Neurofibromatos... NF1 Neurofibromatos... | - | Ann & Robert H Lurie Children's Hospital of Chicago | ||
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. | NCT02777775 | Cutaneous Neuro... Neurofibromatos... Plexiform Neuro... | Skin Biopsy | 18 Years - | Spectrum Health Hospitals | |
| Study of Plexiform Neurofibromas in Neurofibromatosis Type 1 | NCT00006435 | Plexiform Neuro... NF1 | - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | NCT02101736 | NF1 Neurofibromatos... Plexiform Neuro... | Cabozantinib | 3 Years - | University of Alabama at Birmingham | |
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | NCT02544022 | Neurofibromatos... Plexiform Neuro... | 5 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | NCT04590235 | Neurofibromatos... Neurofibroma Pl... | Selumetinib | 3 Years - 99 Years | AstraZeneca | |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain | NCT02471339 | Neurofibromatos... Plexiform Neuro... | Acceptance and ... | 16 Years - 59 Years | National Institutes of Health Clinical Center (CC) | |
| US Selumetinib Registry | NCT05683678 | Neurofibromatos... Plexiform Neuro... | 2 Years - 18 Years | Alexion Pharmaceuticals, Inc. | ||
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study | NCT05825365 | Neurofibromatos... Plexiform Neuro... Post-operative | Selumetinib Placebo | 3 Years - 18 Years | AstraZeneca | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Individual Patient Compassionate Use of Mirdametinib | NCT05028166 | Neurofibromatos... Histiocytic Neo... Other MAP-K Pat... | Mirdametinib (M... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas | NCT02177825 | Plexiform Neuro... | Imatinib Mesyla... | 2 Years - 21 Years | St. Justine's Hospital | |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain | NCT02471339 | Neurofibromatos... Plexiform Neuro... | Acceptance and ... | 16 Years - 59 Years | National Institutes of Health Clinical Center (CC) | |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | NCT02544022 | Neurofibromatos... Plexiform Neuro... | 5 Years - | National Institutes of Health Clinical Center (CC) | ||
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | NCT02544022 | Neurofibromatos... Plexiform Neuro... | 5 Years - | National Institutes of Health Clinical Center (CC) | ||
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | NCT02101736 | NF1 Neurofibromatos... Plexiform Neuro... | Cabozantinib | 3 Years - | University of Alabama at Birmingham | |
| US Selumetinib Registry | NCT05683678 | Neurofibromatos... Plexiform Neuro... | 2 Years - 18 Years | Alexion Pharmaceuticals, Inc. | ||
| Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. | NCT02777775 | Cutaneous Neuro... Neurofibromatos... Plexiform Neuro... | Skin Biopsy | 18 Years - | Spectrum Health Hospitals | |
| Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development | NCT00340522 | Cancer | - 25 Years | National Institutes of Health Clinical Center (CC) | ||
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
